Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuan-Di Halvorsen

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Clinical Pharmacology in Drug Development|February 5, 2024
Results from a Phase 1 Study Assessing the Pharmacokinetics of the Aldosterone Synthase Inhibitor Baxdrostat in Participants with Varying Degrees of Renal FunctionMason W Freeman, Yuan-Di Halvorsen, Mary Bond, et al.
Diabetes, Obesity & Metabolism|June 5, 2019
A 24-week, randomized, double-blind, active-controlled clinical trial comparing bexagliflozin with sitagliptin as an adjunct to metformin for the treatment of type 2 diabetes in adultsYuan-Di Halvorsen, John P Lock, Wenjiong Zhou, et al.
Diabetes, Obesity & Metabolism|July 6, 2023
Bexagliflozin as an adjunct to metformin for the treatment of type 2 diabetes in adults: A 24-week, randomized, double-blind, placebo-controlled trialYuan-Di Halvorsen, Annie L Conery, John Paul Lock, et al.
Diabetes, Obesity & Metabolism|November 22, 2019
A 12-week, randomized, double-blind, placebo-controlled, four-arm dose-finding phase 2 study evaluating bexagliflozin as monotherapy for adults with type 2 diabetesYuan-Di Halvorsen, Geoffrey Walford, Tara Thurber, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|August 22, 2019
Metabolism and disposition of the SGLT2 inhibitor bexagliflozin in rats, monkeys and humansWenbin Zhang, Xiaoyan Li, Haifeng Ding, et al.
Diabetes, Obesity & Metabolism|September 30, 2022
A 96-week, double-blind, randomized controlled trial comparing bexagliflozin to glimepiride as an adjunct to metformin for the treatment of type 2 diabetes in adultsYuan-Di Halvorsen, John Paul Lock, Juan P Frias, et al.
The New England Journal of Medicine|November 7, 2022
Phase 2 Trial of Baxdrostat for Treatment-Resistant HypertensionMason W Freeman, Yuan-Di Halvorsen, William Marshall, et al.
The Annals of Otology, Rhinology, and Laryngology|September 28, 2012
Safety and dosing of bevacizumab (avastin) for the treatment of recurrent respiratory papillomatosisSimon R Best, Aaron D Friedman, Tali Landau-Zemer, et al.
The Annals of Otology, Rhinology, and Laryngology|November 22, 2011
Local injection of bevacizumab (Avastin) and angiolytic KTP laser treatment of recurrent respiratory papillomatosis of the vocal folds: a prospective studySteven M Zeitels, Anca M Barbu, Tali Landau-Zemer, et al.
Stem Cells (Dayton, Ohio)|December 3, 2005
Immunophenotype of human adipose-derived cells: temporal changes in stromal-associated and stem cell-associated markersJames B Mitchell, Kevin McIntosh, Sanjin Zvonic, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Clinical Pharmacology in Drug Development|February 5, 2024
Results from a Phase 1 Study Assessing the Pharmacokinetics of the Aldosterone Synthase Inhibitor Baxdrostat in Participants with Varying Degrees of Renal FunctionMason W Freeman, Yuan-Di Halvorsen, Mary Bond, et al.
Diabetes, Obesity & Metabolism|June 5, 2019
A 24-week, randomized, double-blind, active-controlled clinical trial comparing bexagliflozin with sitagliptin as an adjunct to metformin for the treatment of type 2 diabetes in adultsYuan-Di Halvorsen, John P Lock, Wenjiong Zhou, et al.
Diabetes, Obesity & Metabolism|July 6, 2023
Bexagliflozin as an adjunct to metformin for the treatment of type 2 diabetes in adults: A 24-week, randomized, double-blind, placebo-controlled trialYuan-Di Halvorsen, Annie L Conery, John Paul Lock, et al.
Diabetes, Obesity & Metabolism|November 22, 2019
A 12-week, randomized, double-blind, placebo-controlled, four-arm dose-finding phase 2 study evaluating bexagliflozin as monotherapy for adults with type 2 diabetesYuan-Di Halvorsen, Geoffrey Walford, Tara Thurber, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|August 22, 2019
Metabolism and disposition of the SGLT2 inhibitor bexagliflozin in rats, monkeys and humansWenbin Zhang, Xiaoyan Li, Haifeng Ding, et al.
Diabetes, Obesity & Metabolism|September 30, 2022
A 96-week, double-blind, randomized controlled trial comparing bexagliflozin to glimepiride as an adjunct to metformin for the treatment of type 2 diabetes in adultsYuan-Di Halvorsen, John Paul Lock, Juan P Frias, et al.
The New England Journal of Medicine|November 7, 2022
Phase 2 Trial of Baxdrostat for Treatment-Resistant HypertensionMason W Freeman, Yuan-Di Halvorsen, William Marshall, et al.
The Annals of Otology, Rhinology, and Laryngology|September 28, 2012
Safety and dosing of bevacizumab (avastin) for the treatment of recurrent respiratory papillomatosisSimon R Best, Aaron D Friedman, Tali Landau-Zemer, et al.
The Annals of Otology, Rhinology, and Laryngology|November 22, 2011
Local injection of bevacizumab (Avastin) and angiolytic KTP laser treatment of recurrent respiratory papillomatosis of the vocal folds: a prospective studySteven M Zeitels, Anca M Barbu, Tali Landau-Zemer, et al.
Stem Cells (Dayton, Ohio)|December 3, 2005
Immunophenotype of human adipose-derived cells: temporal changes in stromal-associated and stem cell-associated markersJames B Mitchell, Kevin McIntosh, Sanjin Zvonic, et al.
Pageof 2